Cavity filling mutations at the thyroxine-binding site dramatically increase transthyretin stability and prevent its aggregation - Sant'Anna, R.; Almeida, M.R.; Varejao, N.; Gallego, P.; Esperante, S.; Ferreira, P.; Pereira-Henriques, A.; Palhano, F.L.; De Carvalho, M.; Foguel, D.; Reverter, D.; Saraiva, M.J.; et al. (Scientific Reports, 2017)

DisProt 7.0: A major update of the database of disordered proteins - Piovesan, D.; Tabaro, F.; Mičetić, I.; Necci, M.; Quaglia, F.; Oldfield, C.J.; Aspromonte, M.C.; Davey, N.E.; Davidović, R.; Dosztányi, Z.; Elofsson, A.; Gasparini, A.; et al. (Nucleic Acids Research, 2017)

Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity - Sant'Anna, R.; Gallego, P.; Robinson, L.Z.; Pereira-Henriques, A.; Ferreira, N.; Pinheiro, F.; Esperante, S.; Pallares, I.; Huertas, O.; Almeida, M.R.; Reixach, N.; Insa, R.; et al. (Nature Communications, 2016)